NRGN and Alzheimer disease: Previous studies have shown that synaptic loss occurred at the early stage of AD [4], and it had attracted researchers’ attention to the CSF biomarkers of synaptic function, such as the synaptosomal-associated protein 25 (SNAP-25) [22], neurogranin [23], and GAP-43 [19].